The consumer framing of melatonin as a natural sleeping pill obscures one of the more elegant pieces of receptor pharmacology in human physiology. Melatonin does not sedate. Instead, it acts through two structurally similar but functionally divergent G-protein coupled receptors — MT1 and MT2 — that segregate the hormone’s actions into distinct circuits: one governing sleep initiation and suprachiasmatic nucleus (SCN) firing, the other governing circadian phase resetting and peripheral thermoregulation. Understanding this dichotomy explains why most over-the-counter melatonin doses miss the mark and why selective receptor agonists are emerging as a more rational approach to circadian medicine.
What Are MT1 and MT2 Receptors?
MT1 (encoded by MTNR1A) and MT2 (encoded by MTNR1B) are seven-transmembrane G-protein coupled receptors that bind melatonin with high affinity in the picomolar to low nanomolar range. They share approximately 60% amino acid identity but display markedly different tissue distributions and downstream signaling preferences. MT1 is densely expressed in the suprachiasmatic nucleus, pars tuberalis of the pituitary, and cerebrovascular tissue. MT2 is found in the SCN as well, but also in the retina, hippocampus, and peripheral vasculature. Both couple primarily to Gi/o proteins, inhibiting adenylyl cyclase and reducing cyclic AMP, though MT2 also signals through Gq pathways under some conditions.[1]
The receptors were cloned in the mid-1990s by Reppert and colleagues, who established that the two subtypes mediate fundamentally different aspects of melatonin’s chronobiotic action — a finding that has only become more clinically relevant as selective ligands have entered development.[1]
How MT1 and MT2 Signaling Diverges
MT1 — Sleep Onset and SCN Silencing: Activation of MT1 receptors on SCN neurons hyperpolarizes the cells and suppresses their spontaneous firing rate. This acute inhibition of the central pacemaker is the mechanism by which evening melatonin reduces alerting signals from the SCN and opens the gate to sleep onset. MT1 knockout mice lose the ability of melatonin to suppress SCN neuronal firing, while retaining phase-shifting responses, confirming the receptor-specific dissection of these functions.[2]
MT2 — Circadian Phase Shifting: MT2 receptors mediate the phase-resetting properties of melatonin. When administered in the evening, melatonin advances the circadian phase; when administered in the early morning, it delays it. This biphasic phase-response curve is abolished in MT2 knockout animals but preserved in MT1 knockouts. MT2 signaling appears to act through protein kinase C and modulation of SCN clock gene expression, particularly Per1 and Per2.[2]
Thermoregulation: Melatonin’s role in lowering core body temperature — a prerequisite for sleep consolidation — is mediated largely through MT2 receptors on peripheral vasculature, promoting distal skin vasodilation and heat dissipation. The drop in core temperature that precedes natural sleep onset is tightly correlated with the endogenous melatonin rise, and selective MT2 agonists reproduce this effect.[3]
Sleep Maintenance via MT2 in the Reticular Thalamus: MT2 receptors are enriched in the reticular thalamic nucleus, where their activation promotes non-REM sleep. Selective MT2 agonists in rodents increase NREM sleep duration and depth without affecting REM, distinguishing this action from benzodiazepine-like sedation.[3]
Clinical Evidence
Dose-Response and Receptor Saturation: Endogenous nocturnal melatonin peaks at roughly 60–80 pg/mL — concentrations that saturate MT1 and MT2 receptors. Supraphysiological doses commonly sold over the counter (3–10 mg) produce serum levels 10 to 100 times higher than physiological peak, which does not enhance receptor activation but does prolong receptor exposure, leading to next-day grogginess and possible MT1 desensitization. Physiological doses (0.1–0.3 mg) more closely replicate endogenous signaling and have shown comparable or superior efficacy for sleep onset in controlled studies.[4]
Circadian Phase Disorders: The strongest evidence base for melatonin lies not in primary insomnia but in circadian rhythm sleep-wake disorders — delayed sleep-wake phase disorder, non-24-hour sleep-wake disorder in blind individuals, and jet lag. In these conditions, low-dose melatonin administered several hours before the desired bedtime produces phase advances that align endogenous rhythms with the desired sleep-wake schedule, an effect attributable primarily to MT2 activation.[4]
Ramelteon and Selective Agonists: Ramelteon, an MT1/MT2 agonist with roughly 8-fold greater MT1 affinity than melatonin itself, was approved by the FDA in 2005 for sleep-onset insomnia. Its preferential MT1 activity reduces sleep latency without the phase-shifting or hangover effects associated with higher-dose melatonin, validating the MT1-onset versus MT2-maintenance receptor model in humans.[5]
Type 2 Diabetes Genetic Link: Common variants in MTNR1B (the MT2 gene) are among the most robust genetic risk factors for type 2 diabetes, identified across multiple genome-wide association studies. The risk allele increases MT2 expression in pancreatic beta cells, where MT2 activation suppresses insulin release. This finding has reframed late-evening melatonin supplementation as potentially problematic in individuals who eat close to bedtime, since elevated melatonin during a glucose load impairs insulin secretion.[6]
Safety Profile
Melatonin is generally well tolerated, with a wide therapeutic window and no clear evidence of dependence. The most common side effects — morning sedation, vivid dreams, and headache — appear dose-related and are largely a consequence of supraphysiological dosing. Suppression of endogenous melatonin production has not been reliably demonstrated in short-term use, though long-term high-dose data in humans remain limited.
The MTNR1B-mediated impairment of beta-cell insulin secretion deserves clinical attention. Individuals with prediabetes, type 2 diabetes, or late-night eating habits may experience worsened glucose tolerance when melatonin is taken near a meal. Timing melatonin at least two to three hours after the final meal mitigates this concern.[6]
Drug interactions are largely pharmacokinetic. Melatonin is metabolized primarily by CYP1A2; fluvoxamine and other CYP1A2 inhibitors can raise serum melatonin tenfold or more, while smoking induces CYP1A2 and reduces exposure. Caution is warranted with warfarin, immunosuppressants, and antihypertensives, though clinically significant interactions are uncommon at low doses.
Melatonin vs Other Sleep Approaches
vs Benzodiazepines and Z-Drugs: GABAergic hypnotics produce sedation by potentiating chloride flux at GABA-A receptors, suppressing neuronal activity broadly. They reliably initiate sleep but distort sleep architecture, reduce slow-wave and REM sleep, and carry dependence risk. Melatonin and selective melatonin receptor agonists operate through a fundamentally different mechanism — gating the circadian system rather than imposing pharmacological sedation — and preserve normal sleep architecture.
vs Antihistamines: Over-the-counter sleep aids based on diphenhydramine or doxylamine block H1 receptors, producing sedation but also significant anticholinergic burden, next-day cognitive impairment, and tolerance within days. These agents do not address circadian misalignment, the underlying cause of many sleep complaints.
vs Light Therapy: Bright light in the morning and avoidance of blue light in the evening remain the most powerful chronobiotic interventions available. Light acts through intrinsically photosensitive retinal ganglion cells to suppress endogenous melatonin and reset the SCN directly. Light therapy and properly timed low-dose melatonin are complementary, not competing, and are most effective when used together for circadian rhythm disorders.
vs DSIP and Other Peptides: Peptide approaches to sleep — including delta sleep-inducing peptide and orexin antagonists like suvorexant — target distinct circuits. Orexin antagonists block wake-promoting signals and are increasingly used for sleep-maintenance insomnia. Combination strategies using a low-dose MT1-preferring agonist for onset alongside an orexin antagonist for maintenance represent an emerging rational polypharmacy aligned with the dual-receptor model.
References
- Reppert SM, Weaver DR, Ebisawa T. “Cloning and characterization of a mammalian melatonin receptor that mediates reproductive and circadian responses.” Neuron. 1994;13(5):1177-1185.
- Liu C, Weaver DR, Jin X, et al. “Molecular dissection of two distinct actions of melatonin on the suprachiasmatic circadian clock.” Neuron. 1997;19(1):91-102.
- Ochoa-Sanchez R, Comai S, Lacoste B, et al. “Promotion of non-rapid eye movement sleep and activation of reticular thalamic neurons by a novel MT2 melatonin receptor ligand.” Journal of Neuroscience. 2011;31(50):18439-18452.
- Zhdanova IV, Wurtman RJ, Regan MM, et al. “Melatonin treatment for age-related insomnia.” Journal of Clinical Endocrinology & Metabolism. 2001;86(10):4727-4730.
- Roth T, Seiden D, Sainati S, et al. “Effects of ramelteon on patient-reported sleep latency in older adults with chronic insomnia.” Sleep Medicine. 2006;7(4):312-318.
- Lyssenko V, Nagorny CL, Erdos MR, et al. “Common variant in MTNR1B associated with increased risk of type 2 diabetes and impaired early insulin secretion.” Nature Genetics. 2009;41(1):82-88.
